LEGN logo

Legend Biotech Corporation (LEGN)

$16.11

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LEGN

Market cap

$3.13B

EPS

-0.81

P/E ratio

--

Price to sales

3.52

Dividend yield

--

Beta

0.55154

Price on LEGN

Previous close

$15.99

Today's open

$16.14

Day's range

$15.75 - $16.50

52 week range

$15.75 - $37.50

Profile about LEGN

CEO

Ingrid Zhang

Employees

2900

Headquarters

Bridgewater, New Jersey

Exchange

Nasdaq Global Select

Shares outstanding

194488413

Issue type

American Depository Receipt

LEGN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on LEGN

Legend Biotech: The Market Is Missing The Bigger Picture

Legend Biotech Corporation shares have plunged 34.5% after briefly rallying to $24.3 on November 9, partly amid the broader selloff in AI-related stocks. I continue to take advantage of market pessimism by steadily accumulating LEGN. Sales of LEGN's blockbuster, Carvykti, developed jointly with J&J, increased 8.1% quarter-on-quarter to $710 million.

news source

Seeking Alpha • Nov 17, 2026

news preview

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech NASDAQ: LEGN reported 36% growth in third-quarter global net trade sales of its multiple myeloma treatment CARVYKTI, while executives said slower-than-anticipated gains in earlier-line U.S. patients and international launch delays could temper sales expectations.

news source

MarketBeat • Nov 10, 2026

news preview

Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million Half of CARTITUDE-2 Cohort A patients remained alive and progression-free without further anti-myeloma treatment five years after a single CARVYKTI ® infusion, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM Updated NCCN Guidelines recommend that all patients with multiple myeloma be referred to a T-cell therapy capable center at first relapse for consideration of available therapies Received U.S. FDA IND clearance for LB2501, an investigational CD19/CD20 dual-targeting in vivo CAR‑T therapy for relapsed or refractory B-cell malignancies Appointed Ingrid Zhang as Chief Executive Officer Cash and cash equivalents, and time deposits of approximately $853 million, as of September 30, 2026 BRIDGEWATER, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its third quarter 2026 unaudited financial results and recent highlights.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells BRIDGEWATER, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that multiple abstracts were accepted for the 2026 American Society of Hematology (ASH) Annual Meeting, taking place December 12–15 in New Orleans, Louisiana.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average

From a technical perspective, Legend Biotech Corporation Sponsored ADR (LEGN) is looking like an interesting pick, as it just reached a key level of support. LEGN recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors

After reaching an important support level, Legend Biotech Corporation Sponsored ADR (LEGN) could be a good stock pick from a technical perspective. LEGN surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

news source

Zacks Investment Research • Oct 27, 2026

news preview

Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive

CARVYKTI's quarterly sales reached $710 million, but Legend's high expenses have kept recurring profitability low. Q2 results show improving operating leverage, with collaboration revenue growing faster than associated costs. I rate LEGN a cautious buy, given the commercial growth opportunity but limited margin of safety.

news source

Seeking Alpha • Oct 22, 2026

news preview

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance  IND clearance supports planned U.S. Phase 1/2 study and advances Legend Biotech's in vivo cell engineering platform BRIDGEWATER, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LB2501, an investigational in vivo CAR-T therapy designed to generate CD19/CD20 dual-targeting chimeric antigen receptor T (CAR-T) cells directly within the patient, for the treatment of relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma.

news source

GlobeNewsWire • Oct 15, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Legend Biotech Corporation

Open an M1 investment account to buy and sell Legend Biotech Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LEGN on M1